Literature DB >> 15588874

Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer.

Barbara Bussels1, Annelies Maes, Patrick Flamen, Philippe Lambin, Katrien Erven, Robert Hermans, Sandra Nuyts, Caroline Weltens, Silvia Cecere, Emmanuel Lesaffre, Walter Van den Bogaert.   

Abstract

BACKGROUND AND
PURPOSE: To determine the salivary function, after parotid-sparing radiotherapy (RT), of different regions within the parotid gland and to evaluate dose-function relationships within the parotid glands and between patients. PATIENTS AND METHODS: Sixteen head and neck cancer patients, irradiated between September 1999 and November 2000 using a conformal parotid-sparing technique, were included in this study. Before RT and 7 months after RT (range 6-10 months), a salivary gland scintigraphy was performed in all patients combined with a single photon emission computed tomography (SPECT). The salivary excretion fraction (SEF) was measured, after stimulation, in 8-12 transverse 5mm SPECT slices of each parotid. Loss of salivary excretion fraction (dSEF %) of these slices was calculated as the proportion of SEF after RT as compared to SEF before RT. Since the planning CT-scan and the SPECT-scintigraphy were performed in the same treatment position, the dose to a transverse slice within the parotid gland could be matched to the loss of salivary excretion fraction of that respective slice. A non-linear model was fitted to the dose-loss of function data and the dose resulting in 50% loss of salivary excretion fraction (D50) was calculated.
RESULTS: Before RT, all but one patient presented with normal salivary excretion fractions (SEF) of both parotid glands. Within the same parotid gland, the SEF's of the different slices were almost equal. Seven months after RT, the reduction in SEF was statistically significant (P-value<0.0001). A significant difference in loss of salivary excretion fraction (dSEF) was also observed between both parotid glands (P<0.0001) as a result of the parotid-sparing technique. When plotting the dSEF of a slice versus the dose given to that slice, doses as low as 10-15 Gy could result in a serious loss of function (dSEF>50%). After fitting a non-linear model to these plots, the mean dose resulting in 50% loss of salivary excretion fraction (D50) 7 months after RT was 22.5 Gy. A large inter-patient variability was found in D50.
CONCLUSIONS: Salivary SPECT is a useful tool for the evaluation of the salivary function of different slices within the parotid gland. Before irradiation, the different slices within one parotid gland act as functional sub-units contributing equally to the function of the entire gland. Seven months after an average dose of 22.5 Gy (D50) the functional sub-unit has lost 50% of its excretion fraction. The high inter-patient variability in D50 and the observation that low doses (10-15 Gy) can induce serious loss of function should prompt us in the clinic to reduce the dose to the parotids even lower than the threshold of 22.5 Gy.

Entities:  

Mesh:

Year:  2004        PMID: 15588874     DOI: 10.1016/j.radonc.2004.09.015

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  18 in total

1.  Investigations on parotid gland recovery after IMRT in head and neck tumor patients.

Authors:  Markus Stock; Wolfgang Dörr; Carmen Stromberger; Ulrike Mock; Susanne Koizar; Richard Pötter; Dietmar Georg
Journal:  Strahlenther Onkol       Date:  2010-11-30       Impact factor: 3.621

Review 2.  Radiotherapy dose-volume effects on salivary gland function.

Authors:  Joseph O Deasy; Vitali Moiseenko; Lawrence Marks; K S Clifford Chao; Jiho Nam; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

3.  Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer.

Authors:  Charles B Simone; David Ly; Tu D Dan; John Ondos; Holly Ning; Arnaud Belard; John O'Connell; Robert W Miller; Nicole L Simone
Journal:  Radiother Oncol       Date:  2011-06-12       Impact factor: 6.280

Review 4.  Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers.

Authors:  S A Bhide; K L Newbold; K J Harrington; C M Nutting
Journal:  Br J Radiol       Date:  2012-05       Impact factor: 3.039

5.  Insulin-like growth factor-1 preserves salivary gland function after fractionated radiation.

Authors:  Kirsten H Limesand; Jennifer L Avila; Kerton Victory; Hui-Hua Chang; Yoon Joo Shin; Oliver Grundmann; Rob R Klein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-16       Impact factor: 7.038

6.  Meningioma and breast cancer: survival of patients with synchronous and metachronous meningioma and breast cancer.

Authors:  José Pedro Lavrador; Marta Valente Pinto; Luís Mascarenhas Lemos; Catarina Ribeiro; André Peralta Santos
Journal:  J Neurooncol       Date:  2017-11-08       Impact factor: 4.130

Review 7.  Sensitivity of salivary glands to radiation: from animal models to therapies.

Authors:  O Grundmann; G C Mitchell; K H Limesand
Journal:  J Dent Res       Date:  2009-10       Impact factor: 6.116

8.  Dose-effect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy.

Authors:  Carol-Anne Murdoch-Kinch; Hyugnjin M Kim; Karen A Vineberg; Jonathan A Ship; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-11       Impact factor: 7.038

9.  The effect of significant tumor reduction on the dose distribution in intensity modulated radiation therapy for head-and-neck cancer: a case study.

Authors:  James Mechalakos; Nancy Lee; Margie Hunt; C Clifton Ling; Howard I Amols
Journal:  Med Dosim       Date:  2008-11-24       Impact factor: 1.482

10.  The influence of xerostomia after radiotherapy on quality of life: results of a questionnaire in head and neck cancer.

Authors:  Piet Dirix; Sandra Nuyts; Vincent Vander Poorten; Pierre Delaere; Walter Van den Bogaert
Journal:  Support Care Cancer       Date:  2007-07-06       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.